0 of 5 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
0 of 5 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
You must score 0% to continue. Please click the link below to re-take the quiz
1. Please list your last name and zip code:
2. What is your specialty?
3. How many patients with gastroesophageal cancer do you see each week?
4. Which of the following is NOT currently a standard option for second line therapy after failure of first line fluropyrimidine/platinum-trastuzumab therapy for a patient with persistently HER2+, PDL1 CPS 0 gastroesophageal adenocarcinoma:
5. If one was considering continued anti-HER2 therapy after first progression on trastuzumab, one should repeat HER2 testing in the tissue and/or blood to confirm persistent HER2 positivity: